Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Increased pigmentation may protect skin from UVB, new targets for skin disease treatments were identified, sunscreen ingredients don't affect hormones, TNF-α inhibitors may help diabetic wounds, and certain treatments could prevent chemotherapy-induced hair loss.

In this study, hair follicle-derived mesenchymal stromal cells showed potential for immunomodulation, with equivalent or superior responses compared to those from adipose tissue, suggesting a promising alternative cell source.

In this study, the researchers used a human hair follicle model to demonstrate that T cell stimulation can induce an alopecia areata–like phenotype, with cell proliferation and immune privilege collapse; however, the DHODH inhibitor farudodstat partially mitigated these effects by reducing T cell proliferation.

In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

In this study, AS101 combined with chemotherapy significantly reduced the severity of chemotherapy-induced alopecia in non-small-cell-lung-cancer patients and may involve immune mechanisms related to IL-1 and PGE2.

This study suggests that targeting skin-infiltrated memory phenotype T cells could offer a new therapeutic approach to manage lymphopenia-related diseases like graft-versus-host disease and immune reconstitution inflammatory syndrome.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

This study found that adipose-derived mesenchymal stromal cell secretome, particularly when preconditioned with IFNγ, significantly influences cell motility and anti-inflammatory responses, enhancing its potential as a regenerative therapy.

Regulatory T cells help prevent autoimmunity and have potential for treating autoimmune diseases.

The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

This study found that transfollicular delivery using surfactant-based nanoparticles significantly enhanced antigen stability and immune response compared to other delivery methods, especially when combined with an adjuvant.

This study describes a patient with metastatic renal cell carcinoma who experienced a recurrence of pemphigus vulgaris after receiving interleukin 2 immunotherapy, suggesting a possible link between the treatment and autoimmune disease recurrence.

This review discusses how recent studies use models and experiments to understand immune system signaling, but it reports no new clinical findings; the authors suggest strategies for improving these models.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

This study found that the IL-33/ST2 axis may protect against skin carcinogenesis by promoting cross-talk between epithelial cells and regulatory T cells to minimize mutations and contain tissue damage.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

This review highlights that nano-antioxidants show promise as a treatment strategy for immune-mediated inflammatory diseases, like autoimmune and chronic inflammatory conditions, due to their improved stability and targeted delivery, but notes that further research is necessary to optimize their use and assess long-term safety.

This study suggests that a biomaterial-based approach using microneedles and ion solutions to deliver SiO3 2− ions may disrupt inflammatory cycles and improve outcomes in inflammatory dilated cardiomyopathy (iDCM).

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.